background: the aim of this study was to investigate the prevalence and associated factors of glucocorticoid-induced diabetes mellitus (gidm) in patients with systemic lupus erythematosus (sle) under glucocorticoid therapy. methods: patients with sle who had received high-dose glucocorticoid therapy (prednisolone≥1 mg/kg/day) at rasoul akram and firoozgar hospitals were recruited during 2006-20...

BACKGROUND The use of mycophenolate mofetil (MMF) in autoimmune disease is often limited by adverse effects. In this single-centre, open label, parallel design study, we investigated whether enteric-coated mycophenolate sodium (MS) is better tolerated and therefore more efficacious than MMF in primary systemic vasculitis (PSV) and systemic lupus erythematosus (SLE). METHODS Forty patients wit...

M ycophenolate mofetil (MMF) has become the single most used immunosuppressant in solid-organ transplantation. Despite a well-documented relationship and efficacy (in terms of acute rejection prophylaxis) and exposure to mycophenolic acids (MPA) as measured by area under the curve (AUC), excellent results have been achieved using a fixed-dosage regimen. In the past several years, there has been...

Newer anti-proliferative drugs Deoxyspergualin is a novel anti-proliferative drug derived from bacillus laterosporus that suppresses lymphocyte and macrophage function and impairs neutrophil production (1). Studies in refractory ANCA-associated vasculitis and crescentic glomerulonephritis have demonstrated useful efficacy and in a murine model of spontaneous vasculitis, deoxyspergualin was supe...

Commentary Systemic sclerosis is one of the rheumatic diseases that is associated with the worst prognosis. Systemic sclerosis is divided into localized and systemic forms. Localized scleroderma comprises four subtypes, namely morphea, generalized morphea, linear scleroderma and en coup de saber, and is more commonly encountered in children. Although conversion into systemic sclerosis is very u...

Background: In the past two decades, many new small molecules with immunosuppressive properties have been developed to prevent allograft rejection to be used particularly after organ transplantation. During clinical investigation in these conditions some of these substances have been observed to provide therapeutic efficacy in inflammatory skin disorders, as well. Recently, mycophenolate mofeti...